Loading clinical trials...

Clinical Study of IBI362 in Healthy Chinese Male Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects

NCT04773977•Innovent Biologics (Suzhou) Co. Ltd.

View on ClinicalTrials.gov

Summary

This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

Detailed Description

Pharmacokinetic；Safety

Eligibility

Age

20 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. 20 years old≤ Healthy males≤45 years old
•2. 19 kilograms per meter squared (kg/m²)≤Body Mass Index≤26 kg/m²
•3. Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff

Exclusion Criteria

•1. Subjects who have previously completed or discontinued from this study, or who have used IBI362.
•2. Abnormal vital signs and physical examination during the screening period;
•3. Having cardiovascular, respiratory, liver, kidney, digestive, endocrine, hematologic, neurological, or muscle degenerative diseases can significantly affect drug absorption, metabolism, or elimination, or participation in the study increases risk or interferes with data interpretation.
•4. Have a previous or current mental illness.
•5. A family history of medullary thyroid carcinoma or multiple endocrine tumor syndrome type 2.
•6. There are other factors judged by the investigators that are not suitable for inclusion in this study.

Locations (1)

The Sceond Affiliated Hospital of Nanchang University

Nanchang, China

Key Dates

Start Date

March 3, 2021

Primary Completion Date

March 9, 2021

Completion Date

June 17, 2021

Last Updated

July 8, 2021

Enrollment

ACTUAL participants

Conditions

Overweight/Obesity

Interventions

IBI362 liquid formulation

DRUG

IBI362 lyophilized powder

DRUG

Effects of Cranberry on Gut and Metabolic Health

NCT07460856

Overweight/ObesityMetabolic Syndrome+2 more

View study

RECRUITINGPHASE4

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

NCT03851627

Fatty LiverOverweight/Obesity+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Inclusion Criteria

Exclusion Criteria

Effects of Cranberry on Gut and Metabolic Health

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans

The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution

Mobile Internet Healthcare and Three Disciplines Co-management Intervention for Overweight/Obese Prediabetic Patients

Reducing Diabetes Risk Factors in American Indian Children: Tribal Turning Point